June 30, 2026/
Pancreatin and HEV Transmission, Amoxicillin-Associated Encephalopathy, SGLT2 Inhibitors and Lichen Sclerosus, GLP-1 RA Peripheral Neuropathies and Volvulus, and More
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Pancreatin and HEV Transmission, Amoxicillin-Associated Encephalopathy, SGLT2 Inhibitors and Lichen Sclerosus, GLP-1 RA Peripheral Neuropathies and Volvulus, and More
The year 2025 witnessed significant regulatory actions affecting the safety profiles of multiple gastrointestinal drug classes. From the persistent concerns surrounding PPIs and the emerging risks...
Drug Safety Update on Nasal Decongestants and a Local Case Report on Colistimethate-Induced Neurotoxicity
